DK0470117T3 - Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner - Google Patents

Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner

Info

Publication number
DK0470117T3
DK0470117T3 DK90906216.8T DK90906216T DK0470117T3 DK 0470117 T3 DK0470117 T3 DK 0470117T3 DK 90906216 T DK90906216 T DK 90906216T DK 0470117 T3 DK0470117 T3 DK 0470117T3
Authority
DK
Denmark
Prior art keywords
pct
calcitonin gene
drugs
manufacture
treatment
Prior art date
Application number
DK90906216.8T
Other languages
English (en)
Inventor
Georg Stief
Original Assignee
Georg Stief
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg Stief filed Critical Georg Stief
Application granted granted Critical
Publication of DK0470117T3 publication Critical patent/DK0470117T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/225Calcitonin gene related peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK90906216.8T 1989-04-27 1990-04-21 Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner DK0470117T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3913954A DE3913954A1 (de) 1989-04-27 1989-04-27 Arzneimittel zur behandlung erektiler dysfunktionen
DE3943519A DE3943519A1 (de) 1989-04-27 1989-04-27 Arzneimittel zur behandlung erektiler dysfunktionen

Publications (1)

Publication Number Publication Date
DK0470117T3 true DK0470117T3 (da) 1994-03-14

Family

ID=25880357

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90906216.8T DK0470117T3 (da) 1989-04-27 1990-04-21 Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner

Country Status (11)

Country Link
US (1) US5214030A (da)
EP (1) EP0470117B1 (da)
JP (1) JPH0662429B2 (da)
AT (1) ATE100714T1 (da)
AU (1) AU635533B2 (da)
CA (1) CA2050303C (da)
DE (3) DE3913954A1 (da)
DK (1) DK0470117T3 (da)
HU (1) HU206833B (da)
RU (1) RU2016578C1 (da)
WO (1) WO1990012586A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
CA2080354A1 (en) * 1990-04-10 1991-10-11 John M. Hutson Calcitonin gene related peptide for the treatment of undescended testicles
NZ270871A (en) * 1990-04-25 1999-05-28 Vivus Inc Method for treating erectile dysfunction
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
EP0696919B1 (en) * 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US5567679A (en) * 1993-12-13 1996-10-22 Daly; Theodore J. Use of CGRP in treating alopecia
JPH0827018A (ja) * 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5958877A (en) * 1995-05-18 1999-09-28 Wimalawansa; Sunil J. Method for counteracting vasospasms, ischemia, renal failure, and treating male impotence using calcitonin gene related peptide
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
DE19548345C2 (de) * 1995-12-22 1998-10-15 Henkel Kgaa Verwendung von Mischungen spezieller Emulgatoren und Ölkörpern
US6150338A (en) * 1997-02-13 2000-11-21 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for alleviating erectile dysfunction
US6271211B1 (en) 1997-02-13 2001-08-07 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for regulating penile smooth muscle tone
US7030096B1 (en) * 1997-02-13 2006-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of enhancing relaxation of penile smooth muscle by introduction of DNA encoding maxi-K potassium channel protein
US6239117B1 (en) 1997-02-13 2001-05-29 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for regulating bladder smooth muscle tone
US6211156B1 (en) * 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
US6809079B2 (en) * 2002-01-08 2004-10-26 Vasogenix Pharmaceuticals, Inc. Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
DE202004006803U1 (de) * 2004-04-28 2004-07-08 Brücker, Achim, Dr.med. Kondom mit einer Beschichtung und Zusammensetzung
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
KR101130283B1 (ko) 2009-07-22 2012-03-26 부경대학교 산학협력단 평활근 이완활성을 지닌 칼시토닌 관련 펩타이드

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570600B2 (en) * 1983-06-15 1988-03-17 Celltech Limited Peptides, pharmaceutical compositions,genes,vectors,host organisms, processes for there production and diagnostic reagents
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
GB8327346D0 (en) * 1983-10-12 1983-11-16 Morris H R Peptide
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4687839A (en) * 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents

Also Published As

Publication number Publication date
RU2016578C1 (ru) 1994-07-30
AU5446590A (en) 1990-11-16
HUT59833A (en) 1992-07-28
EP0470117A1 (de) 1992-02-12
CA2050303C (en) 1995-05-30
US5214030A (en) 1993-05-25
EP0470117B1 (de) 1994-01-26
AU635533B2 (en) 1993-03-25
DE3913954A1 (de) 1990-10-31
HU903425D0 (en) 1991-12-30
DE3913954C2 (da) 1991-08-29
ATE100714T1 (de) 1994-02-15
JPH0662429B2 (ja) 1994-08-17
DE3943519A1 (de) 1991-01-17
HU206833B (en) 1993-01-28
JPH04504856A (ja) 1992-08-27
WO1990012586A1 (de) 1990-11-01
DE59004445D1 (de) 1994-03-10

Similar Documents

Publication Publication Date Title
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
DK2016950T3 (da) Farmaceutisk sammensætning omfattende et exendin-4-peptid
HK1003978A1 (en) Composition for the treatment of schizophrenia
DE69006628D1 (de) Pharmazeutische Zusammensetzung, enthaltend Loratadin, Ibuprofen und Pseudoephedrin.
BR9607926A (pt) Composição farmacêutica para o tratamento de hiperfosfatemia uso de carbonato de lantânio processo para a preparação de carbonato de lantânio e carbonato de lantânio
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
PT699686E (pt) Fragmentos de peptido insulinotropico do tipo glucagona biologicamente activos
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
DE69115247D1 (de) Behandlung von fettleibigkeit mit einem alpha-2-adrenergen-agonisten und einem wachstumshormon freigebenden peptid.
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
IT8321289A0 (it) Composizione farmaceutica contenente almeno in parte endotossina detossificata e suo impiego terapeutico.
DK0505497T3 (da) Sårbehandling under anvendelse af biologisk aktive peptider
TR199501630A2 (tr) Peptid p277 benzerleri ve diagnoz ve dibetlerin'lerin tedavisi icin onlari iceren kompozisyonlar.
SE9702401D0 (sv) Pharmaceutical use
EP0981360A4 (en) METHOD FOR PREVENTING GASTRITIS USED BY AMYLIN OR AMYLIN AGONISTS
DE69420145D1 (de) Behandlung präkanzeröser läsionen durch muramylpeptide
ES2109234T3 (es) Metodo de tratamiento de la uveorretinitis autoinmune en el hombre.
ATE221123T1 (de) Glykoprotein-hormonrezeptor-moleküle
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
IL101675A0 (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto